Prognostic tool for identifying high-risk DLBCL patients
Molecular Mechanisms in Malignant Lymphoma- Predict
This study is trying to create a new tool to help doctors find out which patients with diffuse large B cell lymphoma are at high risk of not responding well to their first treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | University Medical Center Goettingen Academic / other |
| Locations | 1 site (Göttingen, Lower Saxony) |
| Trial ID | NCT06526065 on ClinicalTrials.gov |
What this trial studies
This observational study aims to construct and validate a prognostic tool that can accurately identify patients with diffuse large B cell lymphoma (DLBCL) who are at high risk of treatment failure after receiving standard first-line therapy. The study will recruit 500 patients aged 18-80 with de novo large cell B cell lymphoma, collecting clinical data, PET-CT data, and liquid biopsies to determine optimal prognostic factors. The goal is to improve upon current prediction methods by utilizing advanced sequencing techniques and clinical data analysis.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-80 with a histological diagnosis of DLBCL who are about to start guideline-based first-line therapy.
Not a fit: Patients who have already begun treatment with R-CHOP or similar regimens, or those with active HIV or other active cancers, may not benefit from this study.
Why it matters
Potential benefit: If successful, this tool could enable earlier and more reliable identification of high-risk DLBCL patients, allowing for tailored treatment strategies.
How similar studies have performed: Other studies have shown promise in developing prognostic tools for DLBCL, but this approach aims to enhance prediction accuracy beyond existing methods.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Histological diagnosis of DLBCL\&LBCL 2. Planned treatment with guideline-based first-line therapy 3. Patient's consent 4. All genders, Patient age ≥ 18 years 5. Ability to consent Exclusion Criteria: 1. Treatment with R-CHOP/-like regimens already started 2. Relationship of dependence/ direct employment with the investigator 3. Active HIV-infection 4. Presence history of other active cancers (with the exception of basal cell carcinoma of the skin)
Where this trial is running
Göttingen, Lower Saxony
- Universitätsmedizin Göttingen — Göttingen, Lower Saxony, Germany (Recruiting)
Study contacts
- Principal investigator: Lorenz Trümper — PI of the study
- Study coordinator: Anna-Carina Hund
- Email: anna-carina.hund@med.uni-goettingen.de
- Phone: +495513961041
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.